Vitiligo - 白癜風
手指白斑症比其他部位的白斑更難治療。除了美觀之外，白斑是正常現象，並且不會傳染。在皮膚科，最有效的治療方法是光療或雷射治療（準分子），每週 2-3 次，持續至少 1 年。如果您因財務或忙碌而無法經常去醫院，您可以嘗試經批准適合家庭使用的光療機。
眼瞼白斑
手上的白癜風
relevance score : -100.0%
References白斑症是一種常見的皮膚病，因黑色素細胞流失而導致皮膚變白。最近的研究表明，這是一種自體免疫疾病。雖然它通常被視為美容問題，但卻會嚴重影響心理健康與日常生活。2011 年，專家將名為 segmental vitiligo 的一種類型與其他類型分開分類。
Vitiligo is a common skin disorder that causes patches of white skin due to the loss of melanocytes. Recent research shows it's an autoimmune disease. While it's often seen as a cosmetic issue, it can deeply affect mental well-being and daily life. In 2011, experts classified a type called segmental vitiligo separately from others.
Vitiligo is a common skin disorder that causes patches of white skin due to the loss of melanocytes. Recent research shows it's an autoimmune disease. While it's often seen as a cosmetic issue, it can deeply affect mental well-being and daily life. In 2011, experts classified a type called segmental vitiligo separately from others.
活動性白斑症患者有多種治療選擇，例如全身性糖皮質激素、光療和全身性免疫抑制劑。穩定的白斑症患者則可能透過局部皮質類固醇、局部鈣調神經磷酸酶抑制劑、光療或移植手術獲得緩解。近年對白斑發病機制的了解取得進展，促進了標靶治療的發展。目前，JAK 抑制劑被認為最具前景，雖然與其他免疫抑制劑一樣，仍有激活潛伏感染及全身副作用的風險，但其耐受性良好，且能改善功能性結果。正在進行的研究旨在確認參與白斑症發展的關鍵細胞因子（IFN-γ、CXCL10、CXCR3、HSP70i、IL-15、IL-17/23、TNF）。阻斷這些細胞因子已在動物模型及部分患者中顯示出希望。此外，miRNA‑based therapeutics 與 adoptive Treg cell therapy 的相關研究亦在持續進行。
Current models of treatment for vitiligo are often nonspecific and general. Various therapy options are available for active vitiligo patients, including systemic glucocorticoids, phototherapy, and systemic immunosuppressants. While stable vitiligo patients may benefit from topical corticosteroids, topical calcineurin inhibitors, phototherapy, as well as transplantation procedures. Recently, a better understanding of the pathophysiological processes of vitiligo led to the advent of novel targeted therapies. To date, JAK inhibitors are the only category that has been proved to have a good tolerability profile and functional outcomes in vitiligo treatment, even though the risk of activation of latent infection and systemic side effects still existed, like other immunosuppressive agents. Research is in progress to investigate the important cytokines involved in the pathogenesis of vitiligo, including IFN-γ, CXCL10, CXCR3, HSP70i, IL-15, IL-17/23, and TNF, the blockade of which has undergone preliminary attempts in animal models and some patients. In addition, studies on miRNA-based therapeutics as well as adoptive Treg cell therapy are still primary, and more studies are necessary.
Current models of treatment for vitiligo are often nonspecific and general. Various therapy options are available for active vitiligo patients, including systemic glucocorticoids, phototherapy, and systemic immunosuppressants. While stable vitiligo patients may benefit from topical corticosteroids, topical calcineurin inhibitors, phototherapy, as well as transplantation procedures. Recently, a better understanding of the pathophysiological processes of vitiligo led to the advent of novel targeted therapies. To date, JAK inhibitors are the only category that has been proved to have a good tolerability profile and functional outcomes in vitiligo treatment, even though the risk of activation of latent infection and systemic side effects still existed, like other immunosuppressive agents. Research is in progress to investigate the important cytokines involved in the pathogenesis of vitiligo, including IFN-γ, CXCL10, CXCR3, HSP70i, IL-15, IL-17/23, and TNF, the blockade of which has undergone preliminary attempts in animal models and some patients. In addition, studies on miRNA-based therapeutics as well as adoptive Treg cell therapy are still primary, and more studies are necessary.
目前尚無根治白斑症的方法。對於淺色皮膚者，通常建議使用防曬霜並配合化妝品遮蓋。其他可考慮的治療包括類固醇乳膏或光療。
○ 治療
#Phototherapy
#Excimer laser
#Tacrolimus ointment